2. Search Result
Search Result
Results for "

C-terminus

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

37

Peptides

7

Inhibitory Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1136
    Gap19
    5 Publications Verification

    		 Gap Junction Protein Cardiovascular Disease
    Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .
    Gap19
  • HY-P10069
    Ac-pSar12-OH

    		Drug Intermediate ADC Linker Others
    Ac-pSar12-OH is a water-soluble polymer of the polysarcosine class and can be used as a linker. Ac-pSar12-OH is a linear polypeptide derivative composed of 12 arginine units. Ac-pSar12-OH N-terminus is modified with an acetyl group, while the C-terminus retains a free hydroxyl group, which can help enhance the stability of the polypeptide .
    Ac-pSar12-OH
  • HY-157508
    VCP Activator 1
    2 Publications Verification

    		 p97 Others
    VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .
    VCP Activator 1
  • HY-P10909
    Canvuparatide

    MBX 2109

    		 Thyroid Hormone Receptor Endocrinology
    Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .
    Canvuparatide
  • HY-P3815
    Casein Kinase 2 Substrate Peptide
    2 Publications Verification

    		 Casein Kinase Others
    Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .
    Casein Kinase 2 Substrate Peptide
  • HY-P5506
    C5a Receptor agonist, W5Cha

    		Complement System Others
    C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC50=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .
    C5a Receptor agonist, W5Cha
  • HY-P1136A
    Gap19 TFA
    5 Publications Verification

    		 Gap Junction Protein Cardiovascular Disease
    Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .
    Gap19 TFA
  • HY-P1565
    Transdermal Peptide Disulfide

    TD 1 Disulfide(peptide)

    		 Na+/K+ ATPase Inflammation/Immunology
    Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds toNa +/K +-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide can enhance the transdermal delivery of many macromolecules .
    Transdermal Peptide Disulfide
  • HY-P1884
    LL-37, acetylated,amidated

    		Bacterial Infection
    LL-37, acetylated, amidated is a cathelicidin peptide LL-37 acetylated on the N-terminus and amidated on the C-terminus. The single human cathelicidin peptide LL-37 has antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and has wound-healing effects on the host .
    LL-37, acetylated,amidated
  • HY-P1565A
    Transdermal Peptide Disulfide TFA

    TD 1 Disulfide(peptide) TFA

    		 Na+/K+ ATPase Others
    Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na +/K +-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules .
    Transdermal Peptide Disulfide TFA
  • HY-P3624
    Cenderitide

    		Guanylate Cyclase Cardiovascular Disease
    Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .
    Cenderitide
  • HY-P3385
    Rilunermin alfa

    SCB-313

    		 Drug Derivative Apoptosis Cancer
    Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .
    Rilunermin alfa
  • HY-E70565
    O-Glycoprotease

    		Endonuclease Inflammation/Immunology
    O-Glycoprotease is an O-glycoprotein-specific endoprotease that catalyzes the hydrolysis of peptide bonds directly adjacent to the O-polymer in native mucin-type O-glycosylated proteins. O-Glycoprotease sequence is from Akkermansia muciniphila, recombinantly expressed in E.coli, with a 6×His tag at the C-terminus.
    The enzyme maintains high activity between pH 5.5-7.5 and is resistant to 1M NaCl, but is highly sensitive to EDTA (0.5 mM EDTA) and can be inhibited by Zn 2+.
    O-Glycoprotease
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P991676
    Eflumenibep alfa

    DS-2325A

    		 Kallikrein Inflammation/Immunology
    Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus .
    Eflumenibep alfa
  • HY-P991678
    Efpixileukin alfa

    XENP-27564; XMAB-27564

    		 Interleukin Related Inflammation/Immunology
    Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to human immunoglobulin G1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .
    Efpixileukin alfa
  • HY-172193
    UBD1031

    SGC-UBD1031

    		 Deubiquitinase HDAC Inflammation/Immunology Cancer
    UBD1031 (SGC-UBD1031) is a selective USP16/HDAC6-UBD antagonist with a human USP16-UBD IC50 of 10.6 μM, KD value of 48 nM, and a human HDAC6-UBD KD of 16 nM. UBD1031 disrupts ISG15 C-terminus interactions with USP16-UBD and HDAC6-UBD, and exhibits cooperative inhibition of full-length USP16 deubiquitinase activity via USP16-UBD binding. UBD1031 can be used in research on cancer, autoimmune diseases, and Down syndrome .
    UBD1031
  • HY-P3102
    GLP-1(32-36)amide

    		GCGR Metabolic Disease
    GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .
    GLP-1(32-36)amide
  • HY-P10055
    PSMA targeting peptide

    PSMA-1

    		 PSMA Cancer
    PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .
    PSMA targeting peptide
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P991680
    Elipunercept

    		TNF Receptor Inflammation/Immunology
    Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator .
    Elipunercept
  • HY-160550
    DPM-1003

    		Phosphatase Inflammation/Immunology
    DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice .
    DPM-1003
  • HY-P3891
    Substance P (4-11)

    		Neurokinin Receptor Neurological Disease
    Substance P (4-11), the C-terminus fragment of Substance P (HY-P0201), is a Substance P agonist that shows highly selective for NK1 receptors .
    Substance P (4-11)
  • HY-P99963
    Sudubrilimab

    HS636

    		 PD-1/PD-L1 Cancer
    Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
    Sudubrilimab
  • HY-P1321A
    GR231118 TFA

    1229U91 TFA; GW1229 TFA

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA
  • HY-P3932
    [Sar4] Substance P (4-11)

    		Neurokinin Receptor Neurological Disease
    [Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (HY-P0201), is a Substance P agonist .
    [Sar4] Substance P (4-11)
  • HY-E70566
    Protease (Fab Cleaving)

    		Ser/Thr Protease Others
    Protease (Fab Cleaving) is a serine protease expressed recombinantly in E.coli with a 6×His tag at the C-terminus. Protease (Fab Cleaving) specifically digests human IgG1 at a single site above the hinge, generating intact Fab and Fc fragments within two hours without reducing conditions.
    Protease (Fab Cleaving)
  • HY-P10161
    Ac-DMQD-pNA

    		Biochemical Assay Reagents Others
    Ac-DMQD-pNA is a peptide substrate. Both of the recombinant CgCaspase-1 (rCgCaspase-1) and the C-terminus of CgCaspase-1 (rCgCaspase-1-C) exhibits similar caspase activity towards proteolytic substrate Ac-DMQD-pNA and Ac-DEVD-pNA (HY-P1006) .
    Ac-DMQD-pNA
  • HY-P10247
    Amyloid precursor C-terminal peptide

    		Mitochondrial Metabolism Neurological Disease
    Amyloid precursor C-terminal peptide is cleaved from the C-terminus of Amyloid Precursor Protein (APP). Amyloid precursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloid precursor protein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .
    Amyloid precursor C-terminal peptide
  • HY-W440807
    Oleoyl-Gly-Lys-(m-PEG11)-NH2

    		Liposome Others
    Oleoyl-Gly-Lys-(m-PEG11)-NH2 is a PEG-lipid molecule featuring an oleoyl amide linked to a Gly-Lys dipeptide and a methoxy PEG11 chain on the C-terminus of the lysine. The lysine primary amine may be used in a wide variety of reactions with carboxylic acids, NHS esters, and carbonyl groups. The PEG linker provides aqueous solubility.
    Oleoyl-Gly-Lys-(m-PEG11)-NH2
  • HY-P1055
    Pep2-SVKE

    		iGluR Neurological Disease
    Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. Pep2-SVKE does not block AMPA-mediated [ 3H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD [1] [2] [3] [4] [5].
    Pep2-SVKE
  • HY-12135
    Poloxipan

    		Polo-like Kinase (PLK) PIN1 STAT Cancer
    Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
    Poloxipan
  • HY-P5439
    Epsilon-V1-2, Cys-conjugated

    		PKC MARCKS Others
    Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
    Epsilon-V1-2, Cys-conjugated
  • HY-P3102A
    GLP-1(32-36)amide TFA

    		GCGR Metabolic Disease
    GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .
    GLP-1(32-36)amide TFA
  • HY-P2019
    Levitide

    		Neuropeptide Y Receptor Neurological Disease
    Levitide is a neurohormone-like peptide, can be isolated from skin secretions of the South African frog Xenopus laevis. Levitide comes from preprolevitide, is 88 residues long and contains contains the levitide peptide at the C terminus (Glu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2) and the putative signal sequence at the N terminus .
    Levitide
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-P991073
    MEDI-1814

    		Amyloid-β Neurological Disease
    MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    MEDI-1814
  • HY-P10739E
    YRLGRWC

    		Others
    YRLGRWC is a scrambled control of WYRGRLC (HY-P10739C), and it is synthesized by conjugating cysteine to the carboxyl (C-terminus) of YRLGRW (HY-P10739D) .
    YRLGRWC
  • HY-P11284B
    TGN, Cys modified

    		Drug Derivative Neurological Disease
    TGN, Cys modified is a cysteine modified TGN (HY-P11284) on the C-terminus. TGN, a 12-amino acid ligand, is a BBB-penetrating peptide. TGN can be used as a drug delivery vehicle for Alzheimer's disease research .
    TGN, Cys modified
  • HY-117192
    NSC145366 monohydrochloride

    		HSP Fungal Infection
    NSC145366 monohydrochloride is a Hsp90 C-terminal inhibitor. NSC145366 monohydrochloride directly interacts with the C-terminus of Hsp90 and inhibits its chaperone activity. NSC145366 monohydrochloride strongly inhibits the growth of Saccharomyces cerevisiae cog7Δ and cog8Δ strains .
    NSC145366 monohydrochloride
  • HY-W800719
    N-Boc-N'-(PEG1-t-butyl ester)-L-Lysine-amido-Mal

    		Biochemical Assay Reagents Others
    N-Boc-N'-(PEG1-t-butyl ester)-L-Lysine-amido-Mal is the amino acid, lysine, with a maleimide at its C-terminus, a Boc-protecting group on its α-amine, and an amido-PEG1-t-butyl ester on its ε-amine. Maleimide is a thiol-reactive covalent group used to conjugate cysteine residues, while the Boc and the t-butyl ester can be later deprotected to perform further reactions.
    N-Boc-N'-(PEG1-t-butyl ester)-L-Lysine-amido-Mal
  • HY-P1058
    Pep2m

    		iGluR Neurological Disease
    Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression [1] [2] [3] [4] [5].
    Pep2m
  • HY-P992021
    WM-A1-3389

    		Transmembrane Glycoprotein Cancer
    WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer .
    WM-A1-3389
  • HY-P11753
    IKVAVC

    		TGF-beta/Smad Neurological Disease Inflammation/Immunology
    IKVAVC is a derivative peptide of IKVAV with an artificially added cysteine (Cys) at its C-terminus. IKVAVC retains all the biological activities of the original IKVAV, mainly acting as a neural adhesion/differentiation signaling peptide, and is equipped with an engineered linker arm that enables covalent conjugation to molecular materials. IKVAV inhibits the migration and activation of fibroblasts, downregulates the TGF-β1 signaling pathway and endoplasmic reticulum stress, and promotes nerve repair. IKVAV regulates the phenotype of macrophages, shifting them from the pro-inflammatory M1 type to the pro-reparative M2 type .
    IKVAVC
  • HY-E71156
    1,4-Dihydroxy-2-naphthoate polyprenyltransferase

    		Biochemical Assay Reagents Others
    1,4-Dihydroxy-2-naphthoate polyprenyltransferase (EC 2.5.1.74) catalyses a step in the synthesis of menaquinone, in which the prenyl chain synthesized by polyprenyl diphosphate synthase is transferred to 1,4-Dihydroxy-2-naphthoate (DHNA) . 1,4-Dihydroxy-2-naphthoate polyprenyltransferase (EC 2.5.1.74) is an inner membrane protein, with the C-terminus located in the periplasm. 1,4-Dihydroxy-2-naphthoate polyprenyltransferase (EC 2.5.1.74) is highly specific for DHNA but not for a specific length of the prenyl chain.
    1,4-Dihydroxy-2-naphthoate polyprenyltransferase
  • HY-148969
    FPPS-IN-1

    		Others Cancer
    FPPS-IN-1 is a potent non-bisphosphonate Farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 0.2 μM. FPPS-IN-1 can be used for the research of cancers .
    FPPS-IN-1
  • HY-183582
    GB1841

    		Galectin Cancer
    GB1841 is an orally active and selective galectin inhibitor with human galectin-1 Kd of 0.027 μM, human galectin-3 Kd of 0.14 μM, mouse galectin-1 Kd of 0.034 μM and mouse galectin-3 Kd of 1.170 μM. GB1841 can be used for the research of lung cancer .
    GB1841

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: